The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2)

Jonathan A. Winger(QB3), John Kuriyan(Vanderbilt University), Oliver Hantschel(Philipps University of Marburg), Giulio Superti‐Furga(Austrian Academy of Sciences)

BMC Structural Biology

February 24, 2009

10.1186/1472-6807-9-7

Cited by 100

Related Papers

Crystallographic <i>R</i> Factor Refinement by Molecular Dynamics

|Science|1987|2k

Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase

|Science|2000|1.8k

The Conformational Plasticity of Protein Kinases

|Cell|2002|1.8k

An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor Receptor

|Cell|2006|1.6k

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

|Cancer Cell|2002|1.6k